Belkin Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Seconds

Belkin Laser announced that it has completed enrollment in its GLAUrious randomized controlled trial. In this confirmatory, prospective, noninferiority, observer masked RCT a total of 192 patients were randomized across two arms, SLT and DSLT. Six-month follow up for primary endpoint is expected in January of 2022 and 12-month follow up is expected in Q3 of 2022. The GLAUrious trial was supported with the EU Horizon 2020 grant.

Belkin’s innovation solves provides an automated, gentle treatment that can be completed in seconds, making it a unique treatment solution for both glaucoma patients and doctors.

“Our disruptive innovation has the potential to significantly expand the treatment options available to glaucoma patients today by providing an intuitive and time efficient treatment which is unparalleled in its ease of use,” Daria Lemann Blumenthal, CEO and Co-founder of Belkin Laser, said in a company news release.